Evidence map›Paper›PMID 42340866›Full record

ArticleJournal of investigative medicine high impact case reports

Survival After Catastrophic Antiphospholipid Syndrome With Diffuse Alveolar Hemorrhage.

Edy Quizhpe, Franklin Uguña, Javier Velastegui, José Luis Santana, Nelson Moran, Miguel Ochoa, Alex Robalino

Abstract readCase Reports
In one paragraph

Article in Journal of investigative medicine high impact case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Edy QuizhpeCentro de Investigación en Salud Pública y Epidemiología Clínica (CISPEC), Facultad de Ciencias de la Salud "Eugenio Espejo", Universidad UTE, Quito, Ecuador.ORCID 0000-0001-7111-5030
Franklin UguñaHospital General del Sur de Quito, IESS, Quito, Ecuador.
Javier VelasteguiHospital General del Sur de Quito, IESS, Quito, Ecuador.
José Luis SantanaHospital General del Sur de Quito, IESS, Quito, Ecuador.
Nelson MoranHospital General del Sur de Quito, IESS, Quito, Ecuador.
Miguel OchoaHospital General del Sur de Quito, IESS, Quito, Ecuador.
Alex RobalinoHospital General del Sur de Quito, IESS, Quito, Ecuador.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antiphospholipid syndrome is a systemic autoimmune disorder characterized by thrombotic events in the presence of antiphospholipid antibodies including lupus anticoagulant, anticardiolipin, and anti-β2-glycoprotein I antibodies. Catastrophic antiphospholipid syndrome is a rare but life-threatening variant, accounting for less than 1% of antiphospholipid syndrome cases, and is characterized by rapid progressive microvascular thrombosis and multiorgan failure. We report the case of a middle-aged man who developed catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus, presenting with diffuse alveolar hemorrhage, acute kidney injury, vasculitis skin lesions, and severe thrombocytopenia. Management requires intensive care support, immunosuppressive therapy, intravenous immunoglobulin administration, cyclophosphamide administration, and delayed plasmapheresis. Despite multi-organ involvement and guarded prognosis, the patient survived following multidisciplinary management. This case highlights the importance of early recognition, rapid therapeutic intervention, and coordinated interdisciplinary care to improve survival in patients with catastrophic antiphospholipid syndrome.

Indexed as

Antiphospholipid SyndromeHemorrhageLung DiseasesLupus Erythematosus, SystemicPulmonary AlveoliAcute Kidney InjuryCatastrophic IllnessCyclophosphamideHumansImmunoglobulins, IntravenousImmunosuppressive AgentsMaleMiddle AgedMultiple Organ FailurePlasmapheresisThrombocytopeniaCyclophosphamideImmunoglobulins, IntravenousImmunosuppressive Agentsantiphospholipid syndromecatastrophic antiphospholipid syndromesystemic lupus erythematosus

Identifiers

PMID42340866
PMCPMC13305641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.